Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Launched by AUTONOMIC TECHNOLOGIES, INC. · Aug 29, 2012
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject meets CE marked labeling for cluster headache.
- • Subject's typical cluster headache bouts last a minimum of 16 weeks, in the opinion of the Investigator.
- • Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency or dose except to manage tolerability) from Study Enrollment through the completion of the Therapy Evaluation Period.
- • Subject has the ability to read, comprehend and to reliably record information as required by the Protocol.
- • Subject is able to provide written informed consent prior to participation in the study.
- Exclusion Criteria:
- • Subject has had a change in type, dosage or frequency of taking preventive headache medications \< one (1) month prior to Study Enrollment.
- • Per the CE marked labeling: In the opinion of the Investigator, subject has bony facial deformities, inappropriate surgical anatomy or has had facial surgery in the surgical area on the same side as the planned surgery that would prevent the proper placement of the ATI Neurostimulator.
- • Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator.
About Autonomic Technologies, Inc.
Autonomic Technologies, Inc. is a pioneering medical technology company focused on developing innovative neurostimulation therapies for the treatment of chronic pain and other neurological disorders. With a commitment to advancing patient care through cutting-edge research and development, the company leverages its expertise in neuromodulation to create minimally invasive solutions that enhance quality of life. Autonomic Technologies is dedicated to conducting rigorous clinical trials to validate the safety and efficacy of its therapies, aiming to address unmet medical needs and improve outcomes for patients suffering from debilitating conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munster, , Germany
Glostrup, , Denmark
Hamburg, , Germany
Berlin, , Germany
Bochum, , Germany
Essen, , Germany
Jena, , Germany
Kassel, , Germany
Konigstein, , Germany
Munich, , Germany
Munich, , Germany
Patients applied
Trial Officials
Arne May, MD, PhD
Principal Investigator
Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials